Correspondence 0001104659-24-033423 from VYNE Therapeutics Inc. (VYNE) (CIK 0001566044) (VYNE)
VYNE Therapeutics Inc. (VYNE) (CIK 0001566044)
Date: March 12, 2024 · CIK: 0001566044 · Accession: 0001104659-24-033423
AI Filing Summary & Sentiment
File numbers found in text: 333-277609
Letter
VYNE Therapeutics Inc.
685 Route 202/206 N., Suite 301
Bridgewater, New Jersey 08807
March 12, 2024
Via EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Doris Stacey Gama
Re: VYNE Therapeutics Inc.
Registration Statement on Form S-3
File No. 333-277609
Acceleration Request
Requested Date: March 14, 2024
Requested Time: 4:00 p.m. Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Exchange Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-277609) (the “Registration Statement”) to become effective at 4:00 p.m. Eastern Time on Thursday, March 14, 2024, or as soon thereafter as is practicable, or at such other time as its legal counsel, Cooley LLP, may request by telephone to the staff of the Commission.
Once the Registration Statement has been declared effective, please orally confirm that event with Mark Ballantyne of Cooley LLP, counsel to the Registrant, at (703) 456-8084, or in his absence, Minkyu Park, at (212) 479-6588.
[Signature page follows]
Sincerely,
VYNE Therapeutics Inc.
Show Raw Text
CORRESP
1
filename1.htm
VYNE Therapeutics Inc.
685 Route 202/206 N., Suite 301
Bridgewater, New Jersey 08807
March 12, 2024
Via EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Doris Stacey Gama
Re: VYNE Therapeutics Inc.
Registration Statement on Form S-3
File
No. 333-277609
Acceleration Request
Requested
Date: March 14, 2024
Requested Time: 4:00 p.m. Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Exchange Act of 1933,
as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission (the “Commission”)
take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-277609) (the “Registration
Statement”) to become effective at 4:00 p.m. Eastern Time on Thursday, March 14, 2024, or as soon thereafter
as is practicable, or at such other time as its legal counsel, Cooley LLP, may request by telephone to the staff of the Commission.
Once the Registration Statement has been declared effective, please
orally confirm that event with Mark Ballantyne of Cooley LLP, counsel to the Registrant, at (703) 456-8084, or in his absence, Minkyu
Park, at (212) 479-6588.
[Signature page follows]
Sincerely,
VYNE Therapeutics Inc.
By:
/s/ David Domzalski
David Domzalski
Chief Executive Officer
cc:
Tyler Zeronda, Chief Financial Officer, VYNE Therapeutics Inc.
Brian Leaf, Cooley LLP
Mark Ballantyne, Cooley LLP
Minkyu Park, Cooley LLP